Media coverage about GlobeImmune (NASDAQ:GBIM) has been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlobeImmune earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.4705345772645 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of GlobeImmune (GBIM) traded up 9.09% during mid-day trading on Friday, reaching $0.60. The company had a trading volume of 6,210 shares. The company’s market capitalization is $3.45 million. GlobeImmune has a 12-month low of $0.11 and a 12-month high of $1.98. The firm has a 50-day moving average of $0.55 and a 200-day moving average of $0.39.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/02/globeimmune-gbim-given-daily-news-sentiment-rating-of-0-12.html.

GlobeImmune Company Profile

GlobeImmune, Inc is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s segment is the business of developing and commercializing various biopharmaceutical products. The Company’s infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection.

Receive News & Stock Ratings for GlobeImmune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeImmune Inc and related stocks with our FREE daily email newsletter.